Adam Schayowitz Sells 13,832 Zymeworks Shares at $25.85 Each, Totaling $357,557
On October 12, 2026, Adam Schayowitz, EVP and Head of R&D at Zymeworks (ZYME), sold 13,832 shares at $25.85 each, totaling approximately $357,557 according to the SEC's Form 4.
Adam Schayowitz, EVP, Head of R&D of Zymeworks Inc., sold 13,832 shares of the company at $25.85 per share, totaling $357,557 on October 12, 2026.
Who is Adam Schayowitz and What is His Real Role at Zymeworks?
Adam Schayowitz holds the position of Executive Vice President (EVP) and Head of Research and Development (R&D) at Zymeworks Inc., a biopharmaceutical company traded under the ticker ZYME. As EVP, he is part of the senior management team and participates in strategic decisions regarding research projects, scientific collaborations, and investments in cutting-edge technologies.
The R&D leader has direct access to confidential information related to clinical trials, preliminary lab results, licensing agreements, and new drug launch forecasts. These non-public data points can influence market perception of the company's growth prospects. Thus, Adam Schayowitz's role places him in a position where he holds privileged knowledge that could impact the value of Zymeworks shares.
Transaction Details: 13,832 Shares at $25.85 Each
The official form filed with the Securities and Exchange Commission (SEC) indicates that the sale involved exactly 13,832 Zymeworks Inc. shares at a per-share price of $25.85. The transaction was executed on October 12, 2026, and the gross value of the transaction amounts to $357,557. It is important to note that the per-share price ($25.85) differs from the total value ($357,557), two distinct figures presented in the Form 4.
As required by regulations, the executive submitted a Form 4 within two business days following the transaction, as mandated by the SEC's rule for insiders. The document is publicly available on the SEC's EDGAR website at the URL https://www.sec.gov/Archives/edgar/data/2127119/000212711926000006/0002127119-26-000006-index.htm.
Why Insiders Sell Their Shares â Possible Reasons
Share sales by executives can stem from several motives that are not necessarily linked to a negative view of the company. One common reason is portfolio diversification, especially when an executive holds a significant portion of their employer's stock and wishes to reduce their exposure to a single security. Another motivation may be tax planning, where selling shares allows for realizing capital gains at a favorable fiscal time or offsetting previous losses.
Personal liquidity needs, such as financing real estate purchases, covering education expenses, or other significant expenditures, can also prompt an insider to sell part of their holdings. Additionally, the sale might reflect a simple reallocation of assets within a long-term investment strategy, without indicating a definitive signal about the company's future performance. In all cases, the decision to sell remains at the individual's discretion and should not be interpreted as a definitive indicator of the stock's price direction.
How Individual Investors Follow Form 4 Filings
Individual investors can access Form 4 filings through the SEC's EDGAR system, which provides free and real-time access to these documents. Financial data platforms like Bloomberg, Yahoo Finance, or specialized services aggregate this information and offer filters to track insider transactions by ticker, transaction type (buy or sell), and the insider's role.
It is advisable to review multiple filings to identify recurring trends and assess the frequency of buys or sells by the same executive. However, Form 4 data has its limitations: it does not reveal personal motivations behind each transaction and does not guarantee a direct correlation with future stock performance. Investors should therefore combine these insights with other fundamental and technical analysis sources before making investment decisions.
